Donald L. Trump, Douglas M. Potter, Josephia Muindi, Adam Brufsky and Candace S. Johnson Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer Cancer 106
Version of Record online: 5 APR 2006 | DOI: 10.1002/cncr.21890
Epidemiologic and preclinical data indicate that calcitriol may be important in controlling the growth of prostate cancer. A Phase II study in patients with androgen-independent prostate cancer, in which calcitriol at a dose of 12 μg was given Monday, Tuesday, and Wednesday weekly and dexamethasone at a dose of 4 mg was given Sunday, Monday, Tuesday, and Wednesday weekly, disclosed a prostate-specific antigen response rate of 19% and no limiting toxicity.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field